自身免疫疾病药物开发解决方案

免疫系统的核心在于精确调控自身抗原的识别与耐受，这是维护健康的关键。中枢耐受与外周耐受的双重机制共同确保了免疫系统的平衡。然而，当免疫系统受到“免疫预警信号”的挑战时，这种平衡可能受威胁，导致潜在的自身免疫性疾病（Autoimmune Disease, AID）风险。据统计，约有10%的健康人群血清中能检测到低水平的自身抗体，这些抗体虽未引发明显症状，却预示着免疫失衡的可能性。

点击查看ACRO《自身免疫疾病药物开发解决方案》

“为更好生物医药”，ACROBiosystems百普赛斯与全球多家TOP药企建立了长期稳定合作，可提供覆盖早期研发、生产/质量控制、临床前/临床研究的重组蛋白、抗体、细胞株、试剂盒、类器官等产品及一站式服务在内的整体解决方案，为自身免疫疾病药物开发的快速推进提供有力支持。

>>了解ComboX，您身边的通用型研发工具

1. Dunleavy KA, Raffals LE, Camilleri M. Intestinal barrier dysfunction in inflammatory bowel disease: underpinning pathogenesis and therapeutics. Digestive diseases and sciences. 2023, 68 (12):4306-20. https://doi.org/10.1007/s10620-023-08122-w

2. Guo J, Zhang H, Lin W, et al. Signaling pathways and targeted therapies for psoriasis[J]. Signal transduction and targeted therapy, 2023, 8(1): 437. https://doi.org/10.1038/s41392-023-01655-6

3. Ding Q, Hu W, Wang R, et al. Signaling pathways in rheumatoid arthritis: implications for targeted therapy[J]. Signal transduction and targeted therapy, 2023, 8(1): 68. https://doi.org/10.1038/s41392-023-01331-9

4. Huang I H, Chung W H, Wu P C, et al. JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review[J]. Frontiers in immunology, 2022, 13: 1068260. https://doi.org/10.3389/fimmu.2022.1068260

5. Podbielska M, O’Keeffe J, Pokryszko-Dragan A. New insights into multiple sclerosis mechanisms: lipids on the track to control inflammation and neurodegeneration[J]. International journal of molecular sciences, 2021, 22(14): 7319. https: //doi.org/10.3390/ijms22147319

6. Akhil A, Bansal R, Anupam K, et al. Systemic lupus erythematosus: Latest insight into etiopathogenesis[J]. Rheumatology International, 2023, 43(8): 1381-1393. https://doi.org/10.1007/s00296-023-05346-x

7. Zhang Y, Liu W, Lai J, et al. Genetic associations in ankylosing spondylitis: circulating proteins as drug targets and biomarkers[J]. Frontiers in Immunology, 2024, 15: 1394438. https://doi.org/10.3389/fimmu.2024.1394438

8. Warshauer J T, Bluestone J A, Anderson M S. New frontiers in the treatment of type 1 diabetes[J]. Cell metabolism, 2020, 31(1): 46-61. https://doi.org/10.1016/j.cmet.2019.11.017

9. Srivastava A, Makarenkova H P. Innate immunity and biological therapies for the treatment of Sjögren’s syndrome[J]. International journal of molecular sciences, 2020, 21(23): 9172. https: //doi.org/10.3390/ijms21239172

10. Iorio R. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies[J]. Nature Reviews Neurology, 2024, 20(2): 84-98. https://doi.org/10.1038/s41582-023-00916-w